Emerging therapeutic strategies are also exploring novel molecular targets such as aldose reductase (AR) and protein tyrosine phosphatase 1B (PTP1B), two enzymes that play pivotal roles in the pathogenesis and progression of T2DM and its associated complications. Here, PTPN1 is linked to type 2 diabetes mellitus.